Medication-Induced Gastroparesis: A Case Report

Gastroparesis is a commonly diagnosed gastrointestinal disorder with a high prevalence globally and high disease burden to those afflicted with it. Etiologies are variable with idiopathic and diabetes being the most common causes of gastroparesis. Management of gastroparesis depends on the etiology, and accurate diagnosis is required for better targeted therapy. Medication-induced gastroparesis is reversible, and discontinuing the medication is generally curative. This case report discusses 2 cases of medication-induced gastroparesis which were initially diagnosed as diabetic gastroparesis, and thorough history taking revealed the cause to be medication induced. Repeat studies following medication discontinuation revealed improvement in symptoms and resolution of gastroparesis. Further research needs to be done to assess the frequency of misdiagnosing diabetic patients with gastroparesis due to medications, specifically glucagon-like peptide-1 receptor agonists which are increasingly being used in diabetics.

[1]  C. Malbert,et al.  Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations , 2020, Diabetes, obesity & metabolism.

[2]  N. Talley,et al.  Epidemiology and Pathophysiology of Gastroparesis. , 2019, Gastrointestinal endoscopy clinics of North America.

[3]  Q. Cai,et al.  Diabetic Gastroparesis and Nondiabetic Gastroparesis. , 2019, Gastrointestinal endoscopy clinics of North America.

[4]  T. Abell,et al.  Gastroparesis Updates on Pathogenesis and Management , 2017, Gut and liver.

[5]  B. Sloth,et al.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults , 2013, International Journal of Obesity.

[6]  M. Horowitz,et al.  Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones , 2013, Diabetes Care.

[7]  Karen L Jones,et al.  Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  Hye-Kyung Jung,et al.  Incidence , Prevalence , and Outcomes of Patients With Gastroparesis n Olmsted County , Minnesota , From 1996 to 2006 , 2022 .

[9]  Michael Horowitz,et al.  Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. , 2006, The Journal of clinical endocrinology and metabolism.